V. Cottin 1, ⁎ , O. Distler 2, K. Highland 3, M. Gahlemann 4, A. Azuma 5, M. Mayes 6, G. Raghu 7, W. Sauter 8, M. Girard 9, M. Alves 10, E. Clerisme-Beaty 10, S. Stowasser 10, M. Kuwana 11, T. Maher 12
1 Centre national de référence des maladies pulmonaires rares, hôpital Louis-Pradel, université Claude-Bernard Lyon 1, Lyon, France
2 Department of rheumatology, University Hospital Zurich, Zurich, Suisse
3 Respiratory Institute, Cleveland Clinic, Cleveland, États-Unis
4 Boehringer Ingelheim Suisse GmbH, Bâle, Suisse
5 Department of pulmonary medicine and oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japon
6 Division of rheumatology and clinical immunogenetics, University of Texas McGovern Medical School, Houston, Houston, États-Unis
7 University of Washington, Seattle, États-Unis
8 Boehringer Ingelheim Pharma GmbH and Co. KG, Biberach An Der Riss, Allemagne
9 Boehringer Ingelheim France S.A.S, Reims, France
10 Boehringer Ingelheim International GmbH, Ingelheim Am Rhein, Allemagne
11 Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japon
12 National Heart and Lung Institute, Imperial College London and National Institute for Health Research Clinical Research Facility, Royal Brompton Hospital, Londres, Royaume Uni